Arrowhead Pharmaceuticals (NASDAQ:ARWR) Earns Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR - Free Report) in a report published on Tuesday,Benzinga reports. The brokerage currently has a $80.00 price target on the biotechnology company's stock. HC Wainwright also issued estimates for Arrowhead Pharmaceuticals' FY2025 earnings at $1.57 EPS, FY2026 earnings at ($4.18) EPS, FY2027 earnings at ($3.26) EPS, FY2028 earnings at ($3.18) EPS and FY2029 earnings at ($1.28) EPS.

ARWR has been the topic of several other reports. Citigroup cut their target price on shares of Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a "neutral" rating on the stock in a research report on Tuesday, May 13th. Royal Bank of Canada reiterated an "outperform" rating and set a $42.00 price target on shares of Arrowhead Pharmaceuticals in a report on Tuesday, February 11th. Wall Street Zen raised Arrowhead Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Wednesday, May 14th. Chardan Capital reiterated a "buy" rating and issued a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, May 13th. Finally, B. Riley reissued a "buy" rating and issued a $38.00 price target (down previously from $51.00) on shares of Arrowhead Pharmaceuticals in a research report on Friday, February 14th. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $42.13.

Arrowhead Pharmaceuticals Stock Down 1.7%

NASDAQ:ARWR traded down $0.26 on Tuesday, hitting $15.13. 1,230,383 shares of the company's stock were exchanged, compared to its average volume of 1,505,636. Arrowhead Pharmaceuticals has a 52 week low of $9.57 and a 52 week high of $30.41. The company has a market cap of $2.09 billion, a P/E ratio of -2.93 and a beta of 0.89. The company has a debt-to-equity ratio of 7.27, a current ratio of 6.09 and a quick ratio of 6.09. The firm has a 50-day moving average price of $13.32 and a 200-day moving average price of $17.63.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last announced its earnings results on Monday, May 12th. The biotechnology company reported $2.75 earnings per share for the quarter, topping analysts' consensus estimates of ($0.06) by $2.81. The firm had revenue of $542.71 million for the quarter, compared to the consensus estimate of $116.27 million. During the same quarter last year, the business posted ($1.02) EPS. As a group, analysts expect that Arrowhead Pharmaceuticals will post -2.42 EPS for the current fiscal year.

Insider Activity

In other Arrowhead Pharmaceuticals news, CEO Christopher Richard Anzalone sold 133,333 shares of Arrowhead Pharmaceuticals stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $17.02, for a total value of $2,269,327.66. Following the completion of the transaction, the chief executive officer now directly owns 3,773,802 shares of the company's stock, valued at $64,230,110.04. The trade was a 3.41% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders have sold a total of 275,880 shares of company stock worth $4,034,037 over the last 90 days. 4.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Focus Partners Wealth increased its position in Arrowhead Pharmaceuticals by 1,339.5% during the first quarter. Focus Partners Wealth now owns 16,252 shares of the biotechnology company's stock worth $207,000 after buying an additional 15,123 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Arrowhead Pharmaceuticals by 138.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,785,062 shares of the biotechnology company's stock valued at $60,962,000 after purchasing an additional 2,774,933 shares during the period. Empowered Funds LLC grew its stake in Arrowhead Pharmaceuticals by 6.9% during the 1st quarter. Empowered Funds LLC now owns 15,252 shares of the biotechnology company's stock valued at $194,000 after purchasing an additional 979 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in shares of Arrowhead Pharmaceuticals by 34.6% in the first quarter. Goldman Sachs Group Inc. now owns 1,741,666 shares of the biotechnology company's stock worth $22,189,000 after buying an additional 447,456 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd grew its position in shares of Arrowhead Pharmaceuticals by 40.9% in the 1st quarter. Dynamic Technology Lab Private Ltd now owns 26,969 shares of the biotechnology company's stock worth $343,000 after acquiring an additional 7,827 shares in the last quarter. Hedge funds and other institutional investors own 62.61% of the company's stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.